413 related articles for article (PubMed ID: 27676695)
1. Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Zin CS; Rahman NA; Ismail CR; Choy LW
Pain Pract; 2017 Jul; 17(6):774-781. PubMed ID: 27676695
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Changes in trends and pattern of strong opioid prescribing in primary care.
Zin CS; Chen LC; Knaggs RD
Eur J Pain; 2014 Oct; 18(9):1343-51. PubMed ID: 24756859
[TBL] [Abstract][Full Text] [Related]
4. Patterns of initial opioid prescription and its association with short-term and long-term use among opioid-naïve patients in Malaysia: a retrospective cohort study.
Zin CS; Nazar NI; Rahman NSA; Ahmad WR; Rani NS; Ng KS
BMJ Open; 2019 Jul; 9(7):e027203. PubMed ID: 31270113
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study.
Fernandes K; Martins D; Juurlink D; Mamdani M; Paterson JM; Spooner L; Singh S; Gomes T
PLoS One; 2016; 11(12):e0167479. PubMed ID: 27973601
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
[TBL] [Abstract][Full Text] [Related]
7. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
8. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
Kim DY; Song HS; Ahn JS; Ryoo BY; Shin DB; Yim CY; Kim SY
Support Care Cancer; 2010 Feb; 19(2):297-301. PubMed ID: 20213238
[TBL] [Abstract][Full Text] [Related]
9. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
10. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
11. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Sittl R; Nuijten M; Poulsen Nautrup B
Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study.
Lin TC; Ger LP; Pergolizzi JV; Raffa RB; Wang JO; Ho ST
J Formos Med Assoc; 2017 Apr; 116(4):257-265. PubMed ID: 28024664
[TBL] [Abstract][Full Text] [Related]
13. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Corli O; Floriani I; Roberto A; Montanari M; Galli F; Greco MT; Caraceni A; Kaasa S; Dragani TA; Azzarello G; Luzzani M; Cavanna L; Bandieri E; Gamucci T; Lipari G; Di Gregorio R; Valenti D; Reale C; Pavesi L; Iorno V; Crispino C; Pacchioni M; Apolone G;
Ann Oncol; 2016 Jun; 27(6):1107-1115. PubMed ID: 26940689
[TBL] [Abstract][Full Text] [Related]
14. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
Chung CP; Dupont WD; Murray KT; Hall K; Stein CM; Ray WA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):48-53. PubMed ID: 30003613
[TBL] [Abstract][Full Text] [Related]
15. Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011.
Edlund MJ; Austen MA; Sullivan MD; Martin BC; Williams JS; Fortney JC; Hudson TJ
Pain; 2014 Nov; 155(11):2337-43. PubMed ID: 25180008
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
17. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
[TBL] [Abstract][Full Text] [Related]
18. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
19. Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
Chapman CR; Bradshaw DH
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):370-7. PubMed ID: 24143927
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Leppert W; Nosek K
Curr Pharm Des; 2019; 25(30):3216-3224. PubMed ID: 31333114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
